ASCVD


Also found in: Medical.
AcronymDefinition
ASCVDAtherosclerotic Cardiovascular Disease
References in periodicals archive ?
For participants in the lowest third of CVD risk, by both Framingham and ASCVD scores, there was no disability-free survival or cardiovascular benefit from aspirin.
Hazard ratios for disability-free survival with aspirin versus placebo were 0.86 for the group designated high risk by the Framingham score and 0.89 for those considered high risk by the ASCVD equations.
Your doctor will use a tool such as the American College of Cardiology/ American Heart Association (ACC/ AHA) risk calculator and other factors to gauge your long-term risk of ASCVD, determine your need for statin therapy, and guide in the choice of a statin.
Rosenzweig, M.D., from the Hebrew Rehabilitation Hospital in Boston, and colleagues developed clinical practice guidelines for primary prevention of ASCVD and T2DM in patients at metabolic risk for developing these conditions.
The trial included 17,160 patients with T2D, 6,974 of whom had established ASCVD, while the remainder had multiple ASCVD risk factors.
For primary prevention in patients aged 40-75 years, estimation of 10-year ASCVD risk--introduced in the 2013 guidelines--and stratification into one of four categories should set the stage for clinician-patient discussion.
But the document provides much more than an algorithm for treating patients with concomitant ASCVD.
The majority of these lab and imaging markers have weaker or limited evidence for widespread use in comparison to the ASCVD Risk Estimator; so, for the purposes of risk stratification, we shall focus our efforts on using the ASCVD Risk Estimator.
The 2018 AHA/ACC cholesterol guideline represents a step forward in ASCVD prevention--especially in primary prevention, where it provides guidance for risk refinement and personalization.
The science of lipidology from the earliest work of Nikolai Antischkow have expanded its tentacles to various lipid and lipoprotein biomarkers for depicting risk for atherosclerotic cardiovascular diseases (ASCVD).1 Alongside the science also evolved to stratify and quantify the nature and potency of various lipid biomarkers including total cholesterol, triglycerides, LDL-cholesterol(LDLc) and HDL-cholesterol(HDLc).2 Two important lipid related risk assessment emerged for the assessment of ASCVD, which include the villainous one (LDL-cholesterol) and the good HDL-cholesterol.3 Earlier biotechnology did not provide clinically feasible solutions for lipoprotein measurements.
* In February 2019, the European Medicine Agency'sCommittee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Praluent, recommending a new indication to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels as an adjunct to correction of other risk factors in adults with established atherosclerotic cardiovascular disease (ASCVD).
Biotechnology company Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi on Friday jointly announced the receipt of approval from the European Commission (EC) for the new indication for Praluent (alirocumab), to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease (ASCVD).